I am excited to share our latest work published in @NatureComms on the design, synthesis and evaluation of Fucotrim as new cellular fucosulation inhibitors https://t.co/3JG65coLiX
#glycotime#fucose 🔺
The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans https://t.co/D1tPsVANyV - this new review by Benjamin Smith and @CarolynBertozzi highlights experience and therapeutic opportunities in a field that is becoming increasingly tractable
Four weeks ago I shared our work inhibiting cellular fucosylation via the de novo pathway. Today, I proudly share our new fucosylation inhibitors acting via the salvage pathway! Both approaches can help study fucose and are potential therapeutic strategies. #glycotime#fucose 🔺
Proud to share this work from my PhD research. We designed, synthesized and evaluated a new class of fucosylation inhibitors. These compounds are potent, cell active and directly inhibit de novo biosynthesis of fucose. A special thanks to all collaborators! #glycotime#fucose 🔺
A fantastic opportunity with a Glyco Taste: Assistant Professor of Biological Neurochemistry (Tenure Track) https://t.co/o6WR7AK1PK via @Radboud_Uni#glycotime
The Boltje group is hiring! Challenging opportunity for a PhD-candidate interested to work in the field of carbohydrate synthesis, elucidating the mechanism of chemical glycosylations. https://t.co/Uh3t5e2YfI
Targeted Desialylation Overcomes Glyco-Immune Checkpoints and Potentiates the Anticancer Immune Response in Vivo by Carolyn Bertozzi (@CarolynBertozzi) & co-workers
https://t.co/cwhre5FdaP